| Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation in Myelodysplastic Syndromes: Systematic Review and Meta-analysis |
|
Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation |
Myelodysplastic Syndromes (MDS) |
| The case for upfront HLA-matched unrelated donor HCT as a curative option for adult acquired severe aplastic anemia: Upfront MUD HCT for adult severe aplastic anemia |
|
Biology of Blood and Marrow Transplantation: Journal of the American Society of Blood and Marrow Transplantation |
Aplastic Anemia |
| How I Treat Paroxysmal nocturnal hemoglobinuria |
|
Blood |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemia |
|
Blood |
Aplastic Anemia |
| Efficacy and Safety of Venetoclax Plus Azacitidine for Patients With Treatment-Naive High-Risk Myelodysplastic Syndromes |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| Newly revised 2023 MDS response criteria |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| Genetics of Progression From MDS to Secondary Leukemia |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes |
|
Blood |
Myelodysplastic Syndromes (MDS) |
